NasdaqCM:CELCBiotechs
The Bull Case For Celcuity (CELC) Could Change Following Shelf Registration And FDA Review Progress - Learn Why
In early January 2026, Celcuity Inc. filed an omnibus shelf registration covering common and preferred stock, warrants, debt securities and units, shortly after Wells Fargo began coverage and the FDA accepted its NDA under the real-time oncology review program for its PIK3CA asset.
This combination of new financing flexibility and a major regulatory milestone for Celcuity’s lead oncology candidate has sharpened investor focus on how the company might fund and advance its development...